- Home
- PHAT vs MEGI Comparison
PHAT vs MEGI Comparison
Compare PHAT & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | MEGI |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | 371 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 969.8M | 796.8M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHAT | MEGI |
|---|---|---|
| Price | $12.47 | $15.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $19.83 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 125.8K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $7.61 | $13.42 |
| 52 Week High | $18.31 | $15.89 |
Technical Indicators
Market Signals| Indicator | PHAT | MEGI |
|---|---|---|
| Relative Strength Index (RSI) | 67.90 | 50.86 |
| Support Level | $12.31 | $14.95 |
| Resistance Level | $13.26 | $15.46 |
| Average True Range (ATR) | 0.60 | 0.22 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 98.60 | 53.97 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.